Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)Tax ProvisionsTax RateTax RateWages, Salaries and Other
Others
Ratios

Amphastar Pharmaceuticals (AMPH) EPS (Weighted Average and Diluted) (2016 - 2026)

Amphastar Pharmaceuticals has reported EPS (Weighted Average and Diluted) over the past 13 years, most recently at $0.51 for Q4 2025.

  • For Q4 2025, EPS (Weighted Average and Diluted) fell 31.08% year-over-year to $0.51; the TTM value through Dec 2025 reached $2.03, down 33.66%, while the annual FY2025 figure was $2.03, 33.66% down from the prior year.
  • EPS (Weighted Average and Diluted) for Q4 2025 was $0.51 at Amphastar Pharmaceuticals, up from $0.37 in the prior quarter.
  • Over five years, EPS (Weighted Average and Diluted) peaked at $0.91 in Q3 2023 and troughed at $0.1 in Q1 2021.
  • A 5-year average of $0.53 and a median of $0.51 in 2025 define the central range for EPS (Weighted Average and Diluted).
  • Biggest five-year swings in EPS (Weighted Average and Diluted): surged 637.5% in 2021 and later plummeted 52.56% in 2025.
  • Year by year, EPS (Weighted Average and Diluted) stood at $0.4 in 2021, then surged by 62.5% to $0.65 in 2022, then rose by 6.15% to $0.69 in 2023, then increased by 7.25% to $0.74 in 2024, then plummeted by 31.08% to $0.51 in 2025.
  • Business Quant data shows EPS (Weighted Average and Diluted) for AMPH at $0.51 in Q4 2025, $0.37 in Q3 2025, and $0.64 in Q2 2025.